Compare ADMA Biologics Inc (ADMA) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.

The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.

INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.

Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.